


Morgan Lewis



BLOCKBUSTER BIOLOGICS REVIEW ISSUE 12

FDA: Biosimilar Approvals

US Biosimilar Approvals – 29 Total

Drug Name	Approval Date	Drug Name	Approval Date
Riabni (rituximab-arrx)	December 2020	Zirabev (bevacizumab-bvzr)	June 2019
Hulio (adalimumab-fkjp)	July 2020	Kanjinti (trastuzumab-anns)	June 2019
Nyvepria (pegfilgrastim-apgf)	June 2020	Eticovo (etanercept-ykro)	April 2019
Avsola (infliximab-axxq)	December 2019	Trazimera (trastuzumab-qyyp)	March 2019
Abrilada (adalimumab-afzb)	November 2019	Ontruzant (trastuzumab-dttb)	January 2019
Ziextenzo (pegfilgrastim-bmez)	November 2019	Herzuma (trastuzumab-pkrb)	December 2018
Hadlima (adalimumab-bwwd)	July 2019	Truxima (rituximab-abbs)	November 2018
Ruxience (rituximab-pvvr)	July 2019	Udenyca (pegfilgrastim-cbqv)	November 2018

US Biosimilar Approvals – 29 total (cont.)

Drug Name	Approval Date
Hyrimoz (adalimumab-adaz)	October 2018
Nivestym (filgrastim-aafi)	July 2018
Fulphila (pegfilgrastim-jmdb)	June 2018
Retacrit (epoetin alfa-epbx)	May 2018
Ixifi (infliximab-qbtx)	December 2017
Ogivri (trastuzumab-dkst)	December 2017
Mvasi (bevacizumab-awwb)	September 2017

Drug Name	Approval Date
Cyltezo (adalimumab-adbm)	August 2017
Renflexis (infliximab-abda)	May 2017
Amjevita (adalimumab-atto)	September 2016
Erelzi (etanercept-szsz)	August 2016
Inflectra (infliximab-dyyb)	April 2016
Zarxio (filgrastim-sndz)	March 2015

Contacts



Christopher J. Betti, Ph.D.
Chicago
T: +1.312.324.1449
christopher.betti@morganlewis.com



Maria E. Doukas
Chicago
T: +1.312.324.1454
maria.doukas@morganlewis.com



Kelly A. Plummer, Ph.D
Chicago
T: +1.312.324.1490
kelly.plummer@morganlewis.com